Cardiac Calcium Channel Blocker Therapy is a medical approach that plays a pivotal role in managing cardiovascular conditions. These blockers, also known as calcium antagonists, work by inhibiting the influx of calcium ions into the cardiac muscle cells, thereby reducing the workload on the heart. This therapeutic intervention is particularly beneficial in conditions such as hypertension, angina, and certain arrhythmias. By dilating blood vessels and relaxing the heart, calcium channel blockers help improve blood flow and reduce the strain on the cardiovascular system. Clinicians often prescribe these medications as part of a comprehensive treatment plan for individuals with various cardiovascular disorders. As with any medical therapy, it is essential for healthcare providers to tailor the prescription based on the patient's specific health profile and needs, ensuring optimal efficacy while minimizing potential side effects. The evolving landscape of Cardiac Calcium Channel Blocker Therapy continues to contribute significantly to advancements in cardiovascular medicine, enhancing the quality of care for patients with heart-related conditions.
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Fats of Life, the skinny on statins and beyond !
Ahdy Wadie Helmy, Indiana University School of Medicine, United States
Title : Novel ways of cardiovascular risk assessment
Syed Raza, Awali Hospital, Bahrain
Title : Study of pathological cardiac hypertrophy regression
Shuping Zhong, University of Southern California, United States
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Atypical takotsubo cardiomyopathy presenting as st-elevation myocardial infarction
Sana Tariq, Manchester University NHS Foundation Trust, United Kingdom